Androgen receptor mutations in prostate cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Androgen receptor (AR) gene mutations are observed in both early and late-stage prostate cancers.
• These mutations typically retain ligand-dependent transcriptional activity, suggesting a role in disease aggressiveness or treatment resistance.

Purpose of the Study:

• To investigate the role of AR gene mutations and variations in prostate cancer development and progression.
• To explore how AR gene alterations influence response to androgen ablation therapy.

Main Methods:

• Analysis of AR gene mutations in early and late-stage prostate cancer samples.
• Investigation of AR gene variants, including glutamine and glycine repeat lengths.
• Examination of the relationship between AR activity, androgen levels, and tumor cell proliferation.

Main Results:

• AR gene mutations are present in various stages of prostate cancer, retaining transcriptional activity.
• While some tumors harbor AR mutations, others may have variant AR due to alternative splicing.
• Normal AR gene alleles with varying glutamine and glycine repeat lengths appear to mediate androgen's role in early-stage prostate cancer.

Conclusions:

• AR gene mutations may indicate more aggressive prostate cancer or resistance to androgen deprivation.
• The length of glutamine and glycine repeats in the normal AR gene can modulate androgen's effect on tumor cell proliferation.
• Actual AR activity is influenced by AR gene variations, androgen levels, and 5 alpha-reductase activity.